Psychemedics (PMD) Proxy Filing summary

Executive summary

• The proxy statement seeks shareholder approval for a series of proposals, including a reverse and forward stock split, a stock purchase agreement, and the delisting and deregistration of common stock to transition from a public to a private company.

• The primary motivation is to reduce costs associated with public company status, which are deemed unsustainable given declining revenues and limited benefits from public listing.

• The transaction includes a cash-out for holders of fewer than 4,000–6,000 shares at $2.35 per share, a private placement of up to 1,595,744 shares to Mr. Kamin or his designee, and a plan to save approximately $845,000 annually.

• The board and an independent transaction committee, supported by a fairness opinion from Mirus Securities, determined the transaction is fair and in the best interests of all stockholders.

Voting matters and shareholder proposals

• Proposals include re-election of directors, advisory vote on executive compensation, ratification of the new auditor, approval of reverse and forward stock splits, ratification of the stock purchase agreement, and potential adjournment of the meeting.

• Approval of the transaction proposals is required for the company to proceed with deregistration and delisting.

• The board recommends voting in favor of all proposals.

Board of directors and corporate governance

• The board consists of five members, with four independent directors and one employee director.

• An independent transaction committee was formed to oversee the process and negotiations, ensuring procedural fairness.

• The board has audit, compensation, and nominating/governance committees, all composed of independent directors.

• Board diversity and annual self-evaluations are emphasized, with compliance to Nasdaq's diversity rules.